title: Wound healing and antibacterial activities of chondroitin sulfate- and acharan sulfate-reduced silver nanoparticles.
abstract: For topical applications in wound healing, silver nanoparticles (AgNPs) have attracted much attention as antibacterial agents. Herein, we describe a green-synthetic route for the production of biocompatible and crystalline AgNPs using two glycosaminoglycans, chondroitin sulfate (CS) and acharan sulfate (AS), as reducing agents. The synthetic approach avoids the use of toxic chemicals, and the yield of AgNPs formation is found to be 98.1% and 91.1% for the chondroitin sulfate-reduced silver nanoparticles (CS-AgNPs) and the acharan sulfate-reduced silver nanoparticles (AS-AgNPs), respectively. Nanoparticles with mostly spherical and amorphous shapes were observed, with an average diameter of 6.16 ± 2.26 nm for CS-AgNPs and 5.79 ± 3.10 nm for AS-AgNPs. Images of the CS-AgNPs obtained from atomic force microscopy revealed the self-assembled structure of CS was similar to a densely packed woven mat with AgNPs sprinkled on the CS. These nanoparticles were stable under cell culture conditions without any noticeable aggregation. An approximately 128-fold enhancement of the antibacterial activities of the AgNPs was observed against Enterobacter cloacae and Escherichia coli when compared to CS and AS alone. In addition, an in vivo animal model of wound healing activity was tested using mice that were subjected to deep incision wounds. In comparison to the controls, the ointments containing CS-AgNPs and AS-AgNPs stimulated wound closure under histological examination and accelerated the deposition of granulation tissue and collagen in the wound area. The wound healing activity of the ointments containing CS-AgNPs and AS-AgNPs are comparable to that of a commercial formulation of silver sulfadiazine even though the newly prepared ointments contain a lower silver concentration. Therefore, the newly prepared AgNPs demonstrate potential for use as an attractive biocompatible nanocomposite for topical applications in the treatment of wounds.
authors.affiliation: College of Pharmacy and Natural Products Research Institute, Seoul National University, Seoul 151-742, Republic of Korea.
authors.forename: A-Rang
authors.initials: AR
authors.lastname: Im
authors.forename: Jee Young
authors.initials: JY
authors.lastname: Kim
authors.forename: Hyun-Seok
authors.initials: HS
authors.lastname: Kim
authors.forename: Seonho
authors.initials: S
authors.lastname: Cho
authors.forename: Youmie
authors.initials: Y
authors.lastname: Park
authors.forename: Yeong Shik
authors.initials: YS
authors.lastname: Kim
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects; D002809:Chondroitin Sulfates / Q000737:chemistry / Q000494:pharmacology*; D003094:Collagen / Q000737:chemistry; D006025:Glycosaminoglycans / Q000737:chemistry / Q000494:pharmacology*; D006651:Histocytochemistry; D008297:Male; D053768:Metal Nanoparticles; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D010316:Particle Size; D012834:Silver / Q000737:chemistry / Q000494:pharmacology*; D012867:Skin / Q000737:chemistry / Q000473:pathology; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D006025:Glycosaminoglycans; C106771:acharan sulfate; D012834:Silver; D002809:Chondroitin Sulfates; D003094:Collagen